ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

Sebastian E. Sattui1, FRANK HARTMUT DR. BUTTGEREIT2, Merav Lidar3, Kerri Ford4, Stefano Fiore5, Lita Araujo4, Timothy Beukelman6, Fenglong Xie7 and Jeffrey Curtis8, 1University of Pittsburgh, Pittsburgh, PA, 2Charité University Medicine Berlin, Berlin, Germany, 3Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, 4Sanofi, Cambridge, MA, 5Sanofi, Bridgewater, NJ, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL, 8The University of Alabama at Birmingham, Birmingham, AL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Comorbidity, glucocorticoids, Outcome measures, Polymyalgia Rheumatica (PMR), registry

Session Information

Date: Sunday, November 17, 2024

Title: Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the risk of GC toxicity. Frailty, characterized by poor health outcomes and increased vulnerability to stressors is more frequent in PMR (17%)1 than in community dwelling elderly (11%)2. There are limited data on the prevalence of patients with PMR and comorbidities or frailty that may warrant more personalized PMR management (earlier specialist care, screening, lower GC dose/faster taper). Here, we describe the prevalence and management of comorbidities, resulting from or worsening due to long-term GC use, and frailty in PMR.

Methods: Patients aged ≥50 years, without PMR or GCA history, ≥1 inpatient or ≥2 outpatient PMR ≥30–< 365 days apart were identified from Medicare claims from 10/1/2016 to 12/31/2019. Initial GC (prednisone equivalent) use had to be 7.5–25 mg/day ≤30 days after 1st inpatient code or from 1st outpatient to ≤30 days after 2nd outpatient code, ≥200 mg in first ≤30 days and continuous ≥ 4 months.  Patients with seropositive RA, other systemic rheumatic disease, organ transplant, multiple sclerosis, active malignancy treatment or prescription for methotrexate, leflunomide, azathioprine or IL-6 receptor inhibitor during baseline were excluded. 

We report the prevalence of comorbidities (based on diagnosis, procedure or drug codes) that might be relative contraindications to long term GC use and frailty (assessed with a validated claims-based frailty index [CFI]3; defined as CFI ≥0.24), GC use, care by rheumatology, and screening with DXA.

Results: Of 5,499 patients with new onset PMR, at baseline 4.7%, 22.8% and 72.5%, had no, 1 and ≥2 comorbidities, respectively and frailty was seen in 33.8% (Table 1).

Comorbidities and frailty increased over 3 years, with a 4-fold increase in moderate-severe frailty (Table 2). Patients with a higher burden of comorbidities and who were frail were more likely to be on long term GCs (Table 3).

DXA was obtained ≤2 years prior to GC use to ≤3 months after in 42.8%, 72.4%, 56.7%, and 35.6% of all patients, those with low BMD, those with fracture (other comorbidities range: 24.4%–49.6%) and those with moderate-severe frailty, respectively. Although 57.4% of PMR patients visited rheumatology within the first 6 months, 36.7% did not in ≤3 years. Rheumatology consultations for PMR were similar regardless of comorbidity or frailty.

Conclusion: Many new onset PMR patients had or developed comorbidities and frailty over 3 years, possibly due to GC, PMR activity, aging or other factors. Frailty was higher than previously reported in PMR and community dwelling elderly patients. Despite increased vulnerability to GC toxicity, no substantial difference was observed in GC use in frail patients, possibly due to lack of highly effective alternative treatments. Additional measures are needed to improve access to rheumatology care and BMD screening in patients with PMR.

References:

  1. Sattui SE, et al. Rheumatology (Oxford). 2022

  2. Collart RM, et al. J Am Geriatr Soc. 2012

  3. Halawa OA, et al. Ophthalmology. 2023

  4. Kim DH, et al. J Gerontol A Biol Sci Med Sci. 2018

 
Original presentation: EULAR 2024

Supporting image 1

Table 1. Baseline characteristics

Supporting image 2

Table 2. Prevalence of comorbidities and frailty over time

Supporting image 3

Table 3. Proportion of patients on GC and GC dose over time based on baseline comorbidity and frailty status


Disclosures: S. Sattui: Amgen, 1, AstraZeneca, 5, Bristol-Myers Squibb Foundation, 5, Fresenius Kabi, 6, GlaxoSmithKline, 5, Sanofi, 1, 2; F. DR. BUTTGEREIT: AbbVie, 2, 5, 6, Gruenenthal, 2, Horizon Therapeutics, 2, 5, Pfizer, 6, Sanofi, 2, 5, 6, Sparrow Pharmaceuticals, 1, 5; M. Lidar: AbbVie, 6, AstraZeneca, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 6, Pfizer, 6, Sanofi, 6; K. Ford: Sanofi, 3, 11; S. Fiore: sanofi, 3, 11; L. Araujo: Sanofi, 3, 11; T. Beukelman: UCB, 2; F. Xie: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, 5, Bendcare, 2, 5, Eli Lilly, 2, 5, Genentech, 2, 5, GlaxoSmithKline, 2, 5, Horizon, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, Scipher Medicine, 2, 5, Setpoint, 2, 5, UCB Pharma, 2, 5.

To cite this abstract in AMA style:

Sattui S, DR. BUTTGEREIT F, Lidar M, Ford K, Fiore S, Araujo L, Beukelman T, Xie F, Curtis J. Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-management-of-patients-with-comorbidities-and-frailty-in-new-onset-polymyalgia-rheumatica/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-management-of-patients-with-comorbidities-and-frailty-in-new-onset-polymyalgia-rheumatica/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology